Fineline Cube

Follow:
14486 Articles
Otsuka and Lundbeck Win EU Approval for Rxulti in Adolescent Schizophrenia
CompanyDrug

Otsuka and Lundbeck Win EU Approval for Rxulti in Adolescent Schizophrenia

Shanghai Fosun Pharmaceutical Gains NMPA Approval for XH-S003 in PNH Treatment
CompanyDrug

Shanghai Fosun Pharmaceutical Gains NMPA Approval for XH-S003 in PNH Treatment

Trinomab Biotech Launches Xintituo for Tetanus Treatment in Zhuhai
CompanyDrug

Trinomab Biotech Launches Xintituo for Tetanus Treatment in Zhuhai

Tasly Pharma's NR-20201 Receives NMPA Approval for Acute Ischemic Stroke Trial
CompanyDrug

Tasly Pharma’s NR-20201 Receives NMPA Approval for Acute Ischemic Stroke Trial

Jiangsu Aidea's AD108 Receives NMPA Approval for Acute Ischemic Stroke
CompanyDrug

Jiangsu Aidea’s AD108 Receives NMPA Approval for Acute Ischemic Stroke

Insilico Medicine Closes USD110 Million Series E Round to Advance AI-Driven Drug Pipeline
CompanyDeals

Insilico Medicine Closes USD110 Million Series E Round to Advance AI-Driven Drug Pipeline

Sanyou Medical Raises RMB214 Million for Stake in SMTP Technology
CompanyDeals

Sanyou Medical Raises RMB214 Million for Stake in SMTP Technology

Gaush Meditech Receives NMPA Approval for Femtosecond Laser Corneal Refractive Surgery System
CompanyMedical Device

Gaush Meditech Receives NMPA Approval for Femtosecond Laser Corneal Refractive Surgery System

Ipsen Appoints Olivia Brown as Global Head of Neurotoxins, Effective April 1st
Company

Ipsen Appoints Olivia Brown as Global Head of Neurotoxins, Effective April 1st

China Medical System's CMS-D003 Receives NMPA Approval for Clinical Study in oHCM
CompanyDrug

China Medical System’s CMS-D003 Receives NMPA Approval for Clinical Study in oHCM

Zai Lab Submits TIVDAK BLA to China's NMPA for Cervical Cancer Treatment
CompanyDrug

Zai Lab Submits TIVDAK BLA to China’s NMPA for Cervical Cancer Treatment

Haisco Pharmaceutical's HSK44459 Receives NMPA Approval for Psoriasis and Atopic Dermatitis Trials
CompanyDrug

Haisco Pharmaceutical’s HSK44459 Receives NMPA Approval for Psoriasis and Atopic Dermatitis Trials